Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07749742

A Study of MI226 Injection for Abdominal Fat Accumulation

Conditions: Abdominal Fat

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 52

Sponsor: Nanjing Minova Pharmaceutical Co., Ltd.

Location: Peking Union Medical College Hospital Beijing Beijing Municipality

Summary

This is a Phase 1, randomized, double-blind (with open-label sentinel cohorts), placebo-controlled, single-ascending-dose study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of MI226 Injection in participants with abdominal fat accumulation.

Eligibility Criteria

Inclusion Criteria: * Aged ≥18 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07749742). StuddyBuddy aggregates publicly available trial information.